Articles tagged with Blood Cancer
Researchers are developing innovative treatments to starve cancer cells of glucose, a strategy that has shown promising results in breast and colon cancer cases. RNA interference is also being explored as a gene therapy approach to block genes involved in cancer growth, with significant progress made in administering these medicines.
Researchers at Fox Chase Cancer Center discovered the Id3 protein plays a crucial role in directing blood cell progenitors to become gamma-delta T cells. These unique cells possess attributes of both the adaptive and innate arms of the immune system, providing enhanced protection against infections and diseases.
Researchers have found that tumor cells release microvesicles that stimulate the growth of blood vessels, allowing tumors to grow. A new molecule called Diannexin has been identified as a potential therapeutic agent that can block this process and starve tumors.
Researchers at Tel Aviv University discovered that transfusions of 'young' blood –– blood stored for less than 9 days –– increased the odds of survival in animals with leukemia and breast cancer. Fresh blood may be a game-changer in cancer treatment, potentially improving survival rates.
Novel treatments, including fostamatinib disodium, have shown significant clinical activity in treating leukemia and lymphoma. The study found improved response rates and prolonged stable disease in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
A team of Stanford researchers has created a prototype blood scanner that can detect cancer biomarkers in the bloodstream at an early stage of the disease. The system uses magnetic nanotechnology to spot cancer proteins, which is tens to hundreds of times more sensitive than existing commercial devices. This technology holds promise fo...
Researchers found blood transfusions in hospitalized cancer patients increased venous thromboembolism (VTE) and arterial thromboembolism (ATE) rates, comparable to erythropoiesis-stimulating agents (ESAs). This study highlights the need for cautious use of transfusions and exploration of ways to reduce clot risk in cancer patients.
Researchers found that the use of predictive biomarkers and targeted therapies significantly delayed the need for conventional chemotherapy in patients with early-stage but high-risk chronic lymphoid leukemia (CLL). The study resulted in a four-year delay in treatment compared to two years, showing promising results for personalized care.
A landmark clinical trial is underway to test whether a low-molecule-weight heparin can prevent pulmonary embolism in patients receiving chemotherapy on an outpatient basis. The trial aims to identify high-risk cancer patients and demonstrate that blood clots can be prevented with anti-coagulant therapy.
Researchers at Columbia University's Mailman School of Public Health found a strong association between neutropenia, or low white blood count, and women of African descent. This association may affect disparities in disease treatment and outcomes for cancer therapy, particularly among those with breast and colon cancer.
Advances in treatment have led to increased long-term survival for US children diagnosed with acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, or non-Hodgkin lymphoma. Period analysis reveals improved survival rates between 1990 and 2004, with projections suggesting continued progress through molecularly targeted therapies.
The VCU Massey Cancer Center is spearheading a phase II clinical study for certain sub-types of non-Hodgkin's lymphoma, combining the novel drugs bortezomib and vorinostat. The study aims to assess the effectiveness and side effects of this drug regimen in patients whose disease has progressed following treatment with other regimens.
Individuals with low vitamin D levels have a higher risk of death from all causes, according to a study analyzing data from the Third National Health and Nutritional Examination Survey. The analysis found that those with vitamin D deficiency had a 26% increased rate of death compared to those with adequate levels.
The USPSTF recommends against routine prostate cancer screening for men over 75 due to insufficient scientific evidence showing improved health outcomes. Men under 75 may benefit from screening with more evidence needed, according to the updated recommendations.
Researchers have identified microRNAs in blood plasma and serum that can signal the presence of various solid-tumor cancers at an early stage. The discovery has potential to become a new class of biomarkers for early cancer detection, offering advantages over protein-based systems.
University of Manchester researchers have received £1.6 million in funding to study a group of genes identified as playing a key role in leukaemia. The grant will help analyze the common mechanisms of action for patient benefit, potentially leading to the development of targeted therapies.
Scientists are testing a new cancer treatment that uses transfused white blood cells to combat advanced forms of cancer. The treatment, called Leukocyte InFusion Therapy (LIFT), has shown promising results in lab mice and aims to replicate those findings in human patients.
Research found that individuals with gum disease have an increased risk of various cancers, including lung, kidney, and pancreatic cancers. Gum disease was associated with a 14% higher overall cancer risk compared to those without gum disease.
Researchers at the OU Cancer Institute have identified a new gene called RBM3 that causes cancer. The gene is vital for cell division in normal cells but leads to increased tumor formation when overexpressed in cancerous cells.
Recent studies suggest that preoperative chemotherapy can be effective in early breast cancer treatment, but individual responses may vary. Additionally, a case-control study found no increased risk of cancer among frequent blood donors. Furthermore, researchers have identified a novel mechanism to overcome resistance to targeted thera...
Researchers at Fox Chase Cancer Center have discovered that a genetic misalignment can turn a normally quiet developmental gene into a potent driver of T-cell lymphoma in adult mice. The study found that the Dlx5 protein, which is not typically active in healthy adult cells, can be targeted for inhibition to slow cancer growth.
Researchers found a single PSA test can predict advanced prostate cancer with high accuracy, allowing for targeted screening and potentially reducing overdiagnosis. The study revealed that men with higher PSA levels are at increased risk of developing advanced cancer, highlighting the potential for early detection to improve outcomes.
A new study found significant racial and ethnic differences in the treatment and survival of patients with extremity soft-tissue sarcomas. Blacks had lower rates of surgeries that would have saved their arm or leg, higher death rates, and were least likely to receive additional treatments for improved survival.
A recent study found that postmenopausal women taking anastrozole after tamoxifen treatment had a 38% reduced risk of breast cancer recurrence. Additionally, research indicates that blood transfusions may slightly increase cancer risk in the months following the procedure, likely due to underlying undiagnosed cancer.
A recent survey reveals a significant gap in knowledge among primary care physicians regarding rare blood cancers like leukemia and lymphoma. The findings emphasize the importance of education and referrals to specialists in improving patient survival rates. As long-term cancer survivors, patients are at risk of developing second cance...
Researchers found that a specific hormone, TNF-alpha, drives the JAK2 enzyme to cause an often deadly red blood cell cancer called polycythemia vera. The study showed mice with normal TNF-alpha production developed severe bone marrow fibrosis within weeks.
Researchers found that blocking blood vessel growth with an antiangiogenic agent can reduce inflammation and improve antitumor efficacy of oncolytic virus therapy. This approach may increase survival rates for patients with aggressive brain tumors.
Researchers develop compound that targets leukemia at stem-cell level, where malignancy is born, potentially leading to more effective treatments. DMAPT appears to be unique in its ability to kill both dormant and dividing cancer cells without harming healthy blood cells.
A long-term study found that stem cell transplant patients experience decreased sexual function and activity, particularly in females. While males recover partially over time, females remain compromised. The study suggests systemic therapies and chronic graft-versus-host disease contribute to sexual dysfunction.
Researchers at Purdue University have developed a new technology that detects cancer cells in the bloodstream by scanning surface veins. This non-invasive method allows for earlier diagnosis and more accurate monitoring of disease progression, enabling personalized treatment.
Dana-Farber Cancer Institute scientists have identified a protein that prevents the body's immune system from recognizing and attacking Hodgkin lymphoma cells. They are now investigating targeted therapies to disable this molecular 'bodyguard' and boost a patient's ability to fight the blood cancer.
A retrospective study published in The Lancet found no excess risk of cancer among individuals who received blood products from donors with previously diagnosed cancers. The study included over 12,000 exposed individuals and 342,082 unexposed individuals, concluding that long-term cancer survivors might be a safe donor group.
Researchers found bone marrow-derived endothelial progenitor cells (EPCs) play a critical role in early stages of tumor progression. Eliminating EPCs stops cancer growth by preventing blood vessel formation.
A blood test detecting tumor-related proteins may help monitor treatment effectiveness and predict cancer recurrence. Patients with low protein levels were more likely to remain in remission, while those with high increases were at higher risk of cancer return.
Researchers analyzed data on blood donations and recipients in Sweden and Denmark over 34 years, finding no link between cancer risk and blood from precancerous donors. The study provides valuable insights into the safety of blood transfusions and highlights the need for further research on chronic diseases.
Researchers at the National Cancer Institute found that children and young adults with sarcoma are at increased risk of developing thromboembolic events (blood clots) in their veins. The study found that patients whose cancer had spread beyond the original site were more likely to develop a blood clot.
Research suggests that phytochemicals in cruciferous vegetables, such as broccoli and watercress, can stop human prostate cancer cells from growing and inhibit the formation of blood vessels that feed tumors. This study provides promising preliminary evidence for the potential anti-cancer properties of these vegetables.
A new study examines partners of cancer survivors who underwent blood and marrow transplant, finding equal levels of mental health impairment, but with differing treatment outcomes and social support
Researchers have discovered that antibody signals can activate leukocytes to promote cell growth and increase blood supply in precancerous tissues, fueling cancer progression. Potential drugs already being tested may be able to block this pathway, offering a new therapeutic strategy for treating B cell lymphoma and autoimmune diseases.
A team of Boston scientists has discovered that FoxOs are critical in preventing some cancers, maintaining blood vessel stability, and keeping blood-forming stem cells healthy. The researchers found that mice lacking FoxO genes had serious blood abnormalities, including rapid division and depletion of stem cells.
Researchers at Georgetown University Medical Center found that young cancer survivors are at risk of developing unhealthy behaviors, including smoking, lack of exercise, and inadequate sun protection. The study suggests that these behaviors can increase the risk of cancer recurrence and chronic disease in adulthood.
Researchers found that galectin-3 breaks down protective shield MUC1, allowing cancer cells to attach to blood vessel wall and form tumours at secondary sites. The study has significant implications for future drug developments for cancer treatment.
A study presented at the American Society of Hematology Meeting shows Revlimid can provide long-term durable results in MDS patients, helping them achieve blood transfusion independence. After over two years of follow-up, two-thirds of patients were completely freed from the need for blood transfusions.
The study presents positive interim results of using ALDESORT to isolate cord blood stem cells, showing improved overall survival at 90.9% compared to a historical control group. The infusion of cells enriched with ALDESORT appears to improve the speed and efficacy of cord blood transplantations.
Studies presented at the 2006 Annual Meeting of the American Society of Hematology demonstrate significant gains in treating multiple myeloma and related blood cancers. New treatment regimens, including THALOMID, VELCADE, and REVLIMID, show promising results in both newly diagnosed and relapsed patients.
Researchers found that white blood cells in cancer-resistant mice can sense and kill cancer cells through a multi-step process, involving migration, recognition, and physical contact. The discovery suggests that some cancers may share common characteristics that make them vulnerable to this type of immune response.
The use of videoconferencing in a twinning program between Jordan and Canada improved patient care, compliance, and trust. The program showed positive impacts on treatment changes, second opinions, and introduction of new concepts in pediatric oncology.
Acute myelogenous leukemia (AML) patients who have multiple active molecular pathways in their blood and bone marrow samples tend to have a poorer prognosis. Targeting just one pathway is unlikely to be effective due to cross-activation, requiring the development of multi-drug therapies.
A team led by Berkeley Lab's Susan J. Fisher and Joe W. Gray aims to identify cancer-specific proteins and patterns in blood samples for early detection. By combining genome-wide studies with mass-spectrometry-based protein analysis, the team hopes to develop a more accurate test for all cancers.
A new protein in blood serum, human aspartyl beta-hydroxylase (HAAH), has shown promise as a sensitive and specific biomarker for early detection of prostate cancer. HAAH is overexpressed in at least 20 types of cancer and has been linked to tumor growth and invasiveness.
Researchers successfully transplanted white blood cells from cancer-resistant mice into normal mice, eradicating existing and preventing lethal doses of new aggressive cancers. This breakthrough study demonstrates the potential for cancer-resistant-cell therapy to treat highly aggressive types of cancer.
A recent study found that low folate levels and a common mutation in the MTHFR gene may lower the risk of bowel cancer. People with blood levels of folate between the highest and lowest were almost twice as likely to develop the disease compared to those at either extreme.
Researchers identified four genetic subtypes of multiple myeloma, each with distinct gene signatures that predict patient outcomes. The findings provide a clear path for targeted therapies and could lead to improved treatments for this incurable blood cancer.
The center will investigate disparities in modifiable risk factors for breast cancer, particularly among African-American women, and examine demographic, lifestyle, medical, and genetic profiles for obesity. The research aims to develop predictive models and biomarkers to improve early detection and treatment of breast cancer.
Researchers found that fibulins inhibit both tumor growth and blood-vessel formation in mice. The study showed that tumors producing fibulins grew up to 24-45% smaller than control tumors after three weeks.
Scientists have developed nanowire arrays that can detect multiple cancer markers with near-perfect selectivity. These devices can test a mere pinprick of blood in minutes, providing immediate scans and potentially tracking patients' health as treatment progresses.
The blood test aims to identify individuals with improper control of the growth-promoting gene insulin-like growth factor 2 (IGF-2), which is associated with a higher risk of colon cancer. If successful, the test could help monitor those who need invasive colonoscopy or suggest dietary changes to reduce their risk.
A new protein targets tumor vasculature by inducing coagulation when administered systemically, delaying tumor growth and producing some tumor regressions. The treatment shows promise for cancer therapy, adding a powerful punch to the fight against cancer.
A study found that patients with high circulating endothelial cell counts before treatment were more likely to have growing tumors, while those with low counts remained stable. This test may predict patient outcomes and survival, allowing doctors to tailor treatment and spare unnecessary side effects.
Researchers at Johns Hopkins Medicine have developed a new method to educate T-cells in the bone marrow, increasing their ability to recognize and kill cancer cells. The approach shows promise for treating myeloma and potentially other blood and solid tumors.